典晶生物宣布其在美国进行的首个EB-105 临床试验圆满结束

典晶生物

2025/06/11

查看原文

323

EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6R
Improvements in Visual Acuity and Retinal Edema Observed at All Dose Levels
No Safety Issues Observed Following a Single Intravitreal (IVT) Injection
Multiple Ascending Dose Study Planned for Q3 2025 in DME

MOUNTAIN VIEW, Calif.,June 9, 2025 /PRNewswire/ -- Eluminex Biosciences Limited, a clinical-stage protein therapeutics company announced positive topline safety, tolerability, and pharmacodynamic data from a first-in-human single ascending dose study evaluating EB-105 in patients with vision-threatening DME (LOTUS study, Part 1). The study results will be presented at the Clinical Trials at the Summit annual meeting in Las Vegas, NV on June 21, 2025, by retinal specialist Veeral Sheth, MD, Clinical Asst. Professor of Ophthalmology, University of Illinois, and an investigator in the study.

The LOTUS study (Part 1) was an open-label, multicenter, ascending dose study that evaluated a single IVT injection of EB-105 at low (1.6 mg/eye, N=4), mid (4.0 mg/eye, N=5), and high (8.0 mg/eye, N=4) doses in all-comer DME patients (N=13) enrolled from four clinical sites in the United States. Subjects received EB-105 on Day 1 and followed for 3 months. There were no reported drug-related adverse events, dose-limiting toxicities, or serious adverse events including ocular inflammation. The study demonstrated clinically relevant pharmacodynamic activities in all dose groups with sustained overall mean improvement in best-corrected visual acuity (BCVA) and reduction in central retinal subfield thickness (CST). At Month 3 after a single injection of EB-105, maximal reductions in CST from baseline of -103 to -429 µm with maximal gains in BCVA from baseline of +12 to +21 letters were observed across the three dose levels.

"EB-105 has the potential to represent a new generation of tri-specific antibody therapeutics that will allow retinal specialists to treat a broad range of retinal diseases beyond DME in which IL-6-mediated inflammation plays a role including neovascular age-related macular degeneration, retinal vein occlusion, and uveitic macular edema," said Dr. Sheth. Preparations are underway for Part 2 of the LOTUS study that will assess multiple IVT injections in patients with DME. "We are highly encouraged by the initial safety and sustained pharmacodynamic benefits observed in visual acuity improvements and retinal edema reduction following a single injection. Our hope is that multiple injections will provide even further clinical benefits with the added possibility to treat non-responders and increase dosing durability well-beyond the current 16-week benchmark by addressing unchecked IL-6 mediated inflammation," commented Wei Yong Shen, MD, PhD, Chief Scientific Officer of Eluminex Biosciences.

▍About the LOTUS Trial

LOTUS is a multicenter study being conducted in the United States. Part 1 of the study was a single ascending dose study in patients with DME. Part 1 was conducted at five centers in the United States. In addition to participation by Dr. Sheth were the following leading retinal surgeon investigators: Ashkan Abbey, MD, Dallas, TX; David Almeida, MD, Erie, PA; Carl Awh, MD, Nashville, TN; and Charles Wyckoff, MD, Houston, TX. The LOTUS Part 2 study will be conducted with multiple ascending doses (≥ 3 monthly IVT injections) in a similar DME population evaluating the same three dose levels as assessed in Part 1 and will be conducted at up to 10 sites in the United States. The primary objectives of Part 2 will be safety, tolerability and pharmacodynamics and to potentially select a single dose level for Phase 2/3 studies in the future. The study is anticipated to begin enrollment in Q3 2025.

▍About Eluminex Biosciences

Eluminex was founded in early 2020. The company headquarters, research and development (R&D) center, and Good Manufacturing Practices (GMP) manufacturing facilities for recombinant human collagen-based aesthetic products are located in Suzhou Industrial Park BioBAY,China, and the US regional office is located in Mountain View, California. For more information, refer to www.eluminexbio.com.

▍Contact for Investors/Media:

info@eluminexbio.com

▲如需转载，请注明来源——典晶生物。

典晶生物医药科技（苏州）有限公司相关推荐

相关资讯

综合

美财政部正在评估将生物技术纳入对华投资审查

识林

2026-06-22

登上Nature Plants，攻克黄芪甲苷：合成生物学与中药融合的2026年新图景

合成新势力

2026-06-21

2026 EHA | Nikolai Podoltsev教授：Tuspetinib 三联方案优化不耐受化疗 AML 一线治疗

良医汇血液肿瘤资讯

2026-06-20

最新试验分析表明那米司特在肺纤维化患者中展现出生存获益

勃林格殷格翰中国

2026-06-18

恒瑞口服GLP-1新药又一Ⅲ期临床成功，计划今年申报上市！

药圈头条

2026-06-18

重磅官宣！亨斯迈，合并！

兴园化工园区研究院

2026-06-18

恒瑞医药披露口服小分子GLP-1受体激动剂HRS-7535第二项中国关键Ⅲ期2型糖尿病研究（OUTSTAND-2）积极顶线结果

恒瑞医药

2026-06-18

收入超800亿元！两大化工巨头宣布：合并

中国化工报

2026-06-17

贝康医疗PGT-Plus 再获国际权威期刊认证，实现胚胎三倍体与gwUPD检测

BioBAY

2026-06-17

超长效GLP-1竞争格局

医药笔记

2026-06-17

复制链接
微博
微信扫一扫

发表评论

评论区（0）

暂无评论

摩熵医药企业版

50亿+条医药数据随时查

7天免费试用

体验产品

典晶生物

共发布文章：1篇

全球药物研发中心
全球研发数据与行业前沿情报

387,511个

全球在研药物数

695个

本月临床试验数

全球批准的新药

全球首批

各国首批

数据来源：摩熵医药

更新时间：

研发动态

典晶生物宣布其在美国进行的首个EB-105 临床试验圆满结束

相关资讯

全球药物研发中心 全球研发数据与行业前沿情报

最新资讯

VEGF

医药专题

全球药物研发中心
全球研发数据与行业前沿情报